Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.22.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating Costs and Expenses:    
General and administrative $ 6,474 $ 5,029
Research and development 7,800 5,131
Total Operating Costs and Expenses 14,274 10,160
Loss from Operations (14,274) (10,160)
Other Income :    
Interest income 6 44
Total Other Income 6 44
Net Loss (14,268) (10,116)
Net Loss Attributable to Non-controlling Interest (1) (73)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (14,267) (10,043)
Effect of Series A Preferred Stock Price adjustment (7,402) 0
Effect of Warrant exercise price adjustment 0 (880)
Net Loss Attributable to Common Stockholders $ (23,189) $ (12,557)
Net Loss Per Share - Basic $ (0.19) $ (0.66)
Net Loss Per Share - Dilutive $ (0.19) $ (0.66)
Weighted average number of shares outstanding during the period - basic 121,875,042 19,011,362
Weighted average number of shares outstanding during the period - dilutive 121,875,042 19,011,362
Series A Preferred Stock [Member]    
Other Income :    
Preferred Stock Dividends, Income Statement Impact $ (24) $ (254)
Effect of Series A Preferred Stock Price adjustment (7,402) 0
Effect of Warrant exercise price adjustment   (1,000)
Series B Preferred Stock [Member]    
Other Income :    
Preferred Stock Dividends, Income Statement Impact (1,496) (1,380)
Preferred Stock [Member] | Series B Preferred Stock [Member]    
Other Income :    
Net Loss $ 0 $ 0